| P50 | author | Taher Darreh-Shori | Q48268518 |
| | Agneta Nordberg | Q63126486 |
| | Ove Almkvist | Q63409974 |
| P2093 | author name string | R Spiegel | |
| | E Stefanova | |
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| | A new and rapid colorimetric determination of acetylcholinesterase activity | Q26778487 |
| | Mild cognitive impairment: clinical characterization and outcome | Q28140626 |
| | Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial | Q28343193 |
| | Brain Imaging of Attentional Networks in Normal and Pathological States | Q30054760 |
| | Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease | Q32065439 |
| | Imaging cognition II: An empirical review of 275 PET and fMRI studies | Q33180177 |
| | Functional brain imaging as a looking-glass into the degraded brain: reviewing evidence from Alzheimer disease in relation to normal aging | Q34149288 |
| | Frontal-subcortical circuits and human behavior | Q34352930 |
| | Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration | Q34482413 |
| | A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group | Q34744744 |
| | Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group | Q37369200 |
| | Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease | Q41376834 |
| | Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients | Q43513247 |
| | A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. | Q43705809 |
| | Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease | Q43941021 |
| | Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine | Q43948425 |
| | Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit | Q44059395 |
| | Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months | Q44115102 |
| | Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients | Q44301966 |
| | Regulation of attention and response to therapy in dementia by butyrylcholinesterase | Q44385912 |
| | Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. | Q52026628 |
| | A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). | Q52033532 |
| | A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. | Q53239126 |
| | Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. | Q53341838 |
| | A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. | Q53341841 |
| | Harmonization of Dementia Drug Guidelines (United States and Europe): a report of the International Working Group for the Harmonization for Dementia Drug Guidelines. | Q53519755 |
| | Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease | Q57016366 |
| | Alzheimer Disease, Attention, and the Cholinergic System | Q57913199 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 253-261 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients | |
| P478 | volume | 11 | |